Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

What is Trump's current presidential approval rating? According to today's Rasmussen Reports polling, Trump's approval has slipped to 49% approval rating versus 48% that disapprove.

What is Trump's current presidential approval rating? According to today's Rasmussen Reports polling, Trump's approval has slipped to 49% approval rating versus 48% that disapprove.

Vanderbilt tight end Eli Stowers is in elite company. Stowers has been named a preseason first-team All-American by Walter Camp, the oldest college football Al ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock.

Presidential approval ratings show Americans' views during each term. See what the latest polls rated Donald Trump and how it compares to past terms.

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to ...